Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 18 June 2009, Vol. 113, No. 25, pp. 6411-6418.
Prepublished online as a Blood First Edition Paper on February 11, 2009; DOI 10.1182/blood-2008-07-170589.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2008-07-170589v1
113/25/6411    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garzon, R.
Right arrow Articles by Marcucci, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garzon, R.
Right arrow Articles by Marcucci, G.
Related Collections
Right arrow Myeloid Neoplasia
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

MYELOID NEOPLASIA

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1

Ramiro Garzon1,2,*, Shujun Liu1,2,*, Muller Fabbri2,3, Zhongfa Liu4, Catherine E.A. Heaphy1,2, Elisa Callegari2,3, Sebastian Schwind1,2, Jiuxia Pang1,2, Jianhua Yu1,2, Natarajan Muthusamy1,2, Violaine Havelange2,3, Stefano Volinia2,3, William Blum1,2, Laura J. Rush5, Danilo Perrotti2,3, Michael Andreeff6, Clara D. Bloomfield1,2, John C. Byrd1,2, Kenneth Chan4, Lai-Chu Wu3,7, Carlo M. Croce2,3, and Guido Marcucci1,2

1 Department of Medicine, 2 Comprehensive Cancer Center, 3 Molecular Virology, Immunology and Medical Genetics, 4 College of Pharmacy, and 5 Department of Veterinary Biosciences, Ohio State University, Columbus; 6 Section of Molecular Hematology and Therapy, Department of Blood and Bone Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston; and 7 Department of Molecular & Cellular Biochemistry, Ohio State University, Columbus

Aberrant DNA hypermethylation contributes to myeloid leukemogenesis by silencing structurally normal genes involved in hematopoiesis. MicroRNAs (miRNAs) are noncoding RNAs that regulate gene expression by targeting protein-coding mRNAs. Recently, miRNAs have been shown to play a role as both targets and effectors in gene hypermethylation and silencing in malignant cells. In the current study, we showed that enforced expression of miR-29b in acute myeloid leukemia cells resulted in marked reduction of the expression of DNA methyltransferases DNMT1, DNMT3A, and DNMT3B at both RNA and protein levels. This in turn led to decrease in global DNA methylation and reexpression of p15INK4b and ESR1 via promoter DNA hypomethylation. Although down-regulation of DNMT3A and DNMT3B was the result of a direct interaction of miR-29b with the 3' untranslated regions of these genes, no predicted miR-29b interaction sites were found in the DNMT1 3' untranslated regions. Further experiments revealed that miR-29b down-regulates DNMT1 indirectly by targeting Sp1, a transactivator of the DNMT1 gene. Altogether, these data provide novel functional links between miRNAs and aberrant DNA hypermethylation in acute myeloid leukemia and suggest a potentially therapeutic use of synthetic miR-29b oligonucleotides as effective hypomethylating compounds.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

MicroRNA: mIR-ly regulators of DNMT?
Elizabeth A. Griffiths and Steven D. Gore
Blood 2009 113: 6269-6270. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
JCOHome page
M. V. Iorio and C. M. Croce
MicroRNAs in Cancer: Small Molecules With a Huge Impact
J. Clin. Oncol., December 1, 2009; 27(34): 5848 - 5856.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. A. Calin and C. M. Croce
Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes
Blood, November 26, 2009; 114(23): 4761 - 4770.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Visone, L. Z. Rassenti, A. Veronese, C. Taccioli, S. Costinean, B. D. Aguda, S. Volinia, M. Ferracin, J. Palatini, V. Balatti, et al.
Karyotype-specific microRNA signature in chronic lymphocytic leukemia
Blood, October 29, 2009; 114(18): 3872 - 3879.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. A. Griffiths and S. D. Gore
MicroRNA: mIR-ly regulators of DNMT?
Blood, June 18, 2009; 113(25): 6269 - 6270.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020